chrisvoncsefalvay/vaers-outcomes huggingface dataset:
6 patients develop aggressive cases of Cataracts after receiving a Covid-19 vaccine; This spontaneous case was reported by a consumer and describes the occurrence of CATARACT (6 patients develop aggressive cases of Cataracts after receiving a Covid-19 vaccine) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced CATARACT (6 patients develop aggressive cases of Cataracts after receiving a Covid-19 vaccine) (seriousness criterion medically significant). At the time of the report, CATARACT (6 patients develop aggressive cases of Cataracts after receiving a Covid-19 vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The concomitant medication was not reported. The treatment medication was not reported.  It was reported that the Ophthalmologist said that he has had six patients who developed aggressive cases of cataracts after receiving a Covid-19 vaccine.  Company Comment: This spontaneous case concerns a patient, of unknown age and gender,  with no medical history reported, who experienced the unexpected, serious event of cataract (aggressive case) after administration of an unspecified dose of the Moderna mRNA-1273 vaccine. The start date of the event was not provided. No further details were provided. The outcome of the event  was unknown at the time of the report. The rechallenge was unknown as the dose number was not provided. The benefit-risk relationship of the Moderna mRNA-1273 vaccine is not affected by this report. Further information has been requested.   Most recent FOLLOW-UP information incorporated above includes: On 15-Dec-2021: Follow up report contains information of additional reporter were added.; Sender's Comments: This spontaneous case concerns a patient, of unknown age and gender,  with no medical history reported, who experienced the unexpected, serious event of cataract (aggressive case) after administration of an unspecified dose of the Moderna mRNA-1273 vaccine. The start date of the event was not provided. No further details were provided. The outcome of the event  was unknown at the time of the report. The rechallenge was unknown as the dose number was not provided. The benefit-risk relationship of the Moderna mRNA-1273 vaccine is not affected by this report. Further information has been requested.
Pain at injection site; fever 100.4-101.8 F overnight; fatigue; chills; sweat; cough (might be due to seasonal allergies)
pt. rec'd Vaxcelis- previous DTAP/HEPB/POLIO administered at two months of age was Pediarix.  Pt. presents after a spell. Her mother provided the history. She received her 4 mo immunizations this morning. Upon arrival home she was fussy. Mother gave her a dose of Tylenol. Despite that she has been clingy all day, mother has not been able to put her down. She was sleeping in mother's arms and suddenly her lips and face became white/gray. Mother could not feel a heart beat and it appeared that she was not breathing. Mother rubbed her back and jostled her and eventually she came back to herself but it took a few minutes.
Itching, bruising, swelling, hardness, knots, and purplish in color at the injection site; Itching, bruising, swelling, hardness, knots, and purplish in color at the injection site; Itching, bruising, swelling, hardness, knots, and purplish in color at the injection site; Itching, bruising, swelling, hardness, knots, and purplish in color at the injection site; Itching, bruising, swelling, hardness, knots, and purplish in color at the injection site; Itching, bruising, swelling, hardness, knots, and purplish in color at the injection site; This is a spontaneous report from a contactable pharmacist.   A 69-year-old female patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13) (Batch/lot number: CD0412, Expiry Date: Jan2022) intramuscular at 0.5 ml, single on 28Dec2019 for immunisation. Medical history none. There were no concomitant medications. On 02Jan2020, the patient experienced itching, bruising, swelling, hardness, knots, and purplish in color at the injection site with outcome of not recovered. Therapeutic measures were taken as a result of itching, bruising, swelling, hardness, knots, and purplish in color at the injection site included Tylenol, the events would go away, but then they come back.
On Saturday, after the Vaccine, my right ring finger started itching and turned black and blue on the palm side, eyes starting itching. On Sunday, it started to move to the top side of my finger. My finger was cold.  Went to the doctor and she wanted me to see a Vascular doctor and to have test run to make sure there was not a blood clot in that finger.  Went to the ER on Wednesday and had the test ran.  Will see a R
Clinical Summary Patient  is a 82 y.o. female with a history of CHF, COPD, HTN, Chronic Pain, Left Knee Arthritis, who presented to RMH 1/17/2023 with 3-4 days of left thigh pain, left hip pain, fevers, chills, rigors. Found to have (+)COVID test and L Iliopsoas tear with inflammation.    1. Left Ileopsoas Tear:  presented to St. Ann's 1/12/22 with left thigh pain (discharged home) 3-4 days of fevers, chills, rigors prior to admit. CT-A/P 1/18/23: left iliopsoas inflammation from L3 level to insertion on proximal femur with fluid-density. MRI L hip with acute near full thickness tear of L iliopsoas tendon without infectious process. Ortho followed and recommended conservative care with outpatient follow up. 2. Acute on Chronic Left Knee Pain: Known osteoarthritis of both knees s/p Right TKA 8/23/21 with Dr. Underwent L knee aspiration 1/18/2023 with no evidence of septic arthritis.   3. Acute on Chronic DDD: CT A/P 1/18/23: severe spinal canal stenosis at L2-L5.  MRI Lumbar-Spine 1/18/23 severe central canal stenosis throughout L spine. Given back pain at baseline and no neurologic symptoms, defer to outpatient workup. 4. COVID-19 Pneumonia: Vaccinated (Pfizer x4 last 10/2021) symptom onset 1/16/23, (+)test 1/18/23, admit CXR negative for airspace disease. Discharged with Paxlovid therapy. To hold home statin and trazodone until completion of therapy.    5. Hx of Post-Operative AFIB: Diagnosed during right TKA in 8/2021, not on long term systemic AC per PCP.   6. COPD: Stable  7. HTN: Continued home Losartan/hydrochlorothiazide 8. Abnormal Imaging: MRI 1/18/2023 noted indeterminate nodular lesions within uterus, outpatient follow up
Pt.c/o rash, chapped lips, that developed into blisters, and then skin sloughing.  Went to ER.  DX: Steven-Johnson Disease.  Sent to Burn Unit. Remains intubated presently. Unsure if vaccines are contributory to illness.
Approx 2pm flu vaccine given approx 2:20 patient experiencing itching all over, red spots noted on face and neck.  Epinephrine  1ml given per standing order.  O2 administered.  Patient sent to ED per nurse practioner
Patient experienced numbness in left arm after administration. Symptoms resolved within the 15 minute monitoring period after administration. Patient received 0.2ml of undiluted Pfizer Pediatric vaccine.
Information has been received on 14-JUN-2017 from a lawyer and a female patient of unknown age regarding a case in litigation.  It is complained and alleged that the patient was inoculated with ZOSTAVAX (dose, route, lot number and expiration date were not reported) on or about 05-MAY-2012 at a pharmacy as recommended for routine adult health maintenance for the prevention of shingles. The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. On or about 10-JUL-2012, the patient was treated by a nurse practitioner at a hospital for a vesicular outbreak that was diagnosed as severe shingles. On or about 14-JUL-2014, the patient was treated by a nurse practitioner at a hospital for worsening symptoms, at which time the diagnosis of shingles was affirmed as being severe. The patient was prescribed hydrocodone-acetaminophen, valaciclovir and oxycodone-acetaminophen (PERCOCET) for management of her painful symptoms. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering and other damages. Additional information has been requested.
Previous Thyroid issues. However after the vaccine I went from Hyperthyroid to Hypothyroid due to over medication that was prescribed that started experiencing severe anxiety which has caused me to have extreme OCD which I am still experiencing. Anxiety has gotten progressively worse over the course of 11 months. Taking Pristiq 25mg x day, Levoxyl 50mcg Tyrosine 13 mcgs.
Patient fainted after administration of vaccine last for 30 second. No injury happen due to fainting after 30 second. Patient alert, oriented with mild headache x 2-3minute. BP=117/60 HR=78 RR=26 SO2=100%. Pt observed for 10 minute. Asymptomatic. Discharged.
He got the vaccine, had no reaction at all.  After 4 days he noticed it was messing with his blood sugar.  He had a lot of sweats, itching, high levels up to 396 and lows to 48 within the last 2 days.  Today so far he seems to be okay other than blood sugar of 340.  He did call his doctor who told him to take an extra pill and then to reread it at noon and call him back.
Loss of taste and smell.; Severe headache.; Loss of taste and smell.; This is a spontaneous report received from a contactable consumer, the patient. A 53-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: ER8730) via an unspecified route of administration in the left arm on 23Mar2021 at 12:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as no. The patient did not receive any other medications within 2 weeks of vaccination. The patient did not have allergies to medications, food, or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6200 59267-1000) via an unspecified route of administration in the left arm on 02Mar2021 at 11.00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any vaccination within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination the patient had not been tested for COVID-19. On 24Mar2021 at 06.00, the patient experienced loss of taste and smell and severe headache. The patient did not receive any treatment for the reported events. Adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events loss of taste and smell and severe headache was not resolved at the time of report. No follow-up attempts are needed. No further information is expected.
fever 103.8 per mother red, swollen area at site, quarter size, started the night following vaccines into next morning.
got really sick the next day after the 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (got really sick the next day after the 2nd dose) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039A21A and 031A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 19-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Apr-2021, the patient experienced ILLNESS (got really sick the next day after the 2nd dose). At the time of the report, ILLNESS (got really sick the next day after the 2nd dose) outcome was unknown.            Concomitant medications were not provided.  Treatment information was not provided.   This case was linked to MOD-2021-406663 (Patient Link).
Patient reports that about 2-3 days after his Hep B shot he saw a red circle around the site of the injection. A few days after that he noted a sensation of his hands and top of feet burning and the skin began to slough. A few days later he noted increased swelling of his legs.
The morning after vaccination patient awoke with floater the shape of a jellyfish in my eye and sparkly shooting around the outer ring of my left eye.
Initial unsolicited report received from a healthcare professional via Pfizer (under the Mnufacturer report number: 2016295524) on 16 Jun 2016. This case involves a patient (age and gender not reported) who was vaccinated with Tetanus (lot number, expiry date, dose, dose series detail, route and site of administration were not reported) on an unknown date. The medical history and concomitant medications were not reported. It was reported that on an unknown date (unspecified timeframe after vaccination), the patient experienced allergy to the vaccine. The lab data and corrective treatment were not reported. The outcome of the event was not reported. List of documents held by sender: none.
1st dose 20sep2022, 2nd 12Oct2022; This case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 12-month-old male patient who received Flu Seasonal QIV Quebec (FluLaval Quadrivalent 2022-2023 season) (batch number 79ED9, expiry date 30th June 2023) for prophylaxis.   Co-suspect products included flu seasonal qiv quebec pre-filled syringe device (Flulaval Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis.   Concomitant products included INFLUENZA VACCINE INACT (FLULAVAL QUADRIVALENT).   On 12th October 2022, the patient received the 2nd dose of FluLaval Quadrivalent 2022-2023 season and Flulaval Tetra Pre-Filled Syringe Device. On 12th October 2022, unknown after receiving FluLaval Quadrivalent 2022-2023 season and Flulaval Tetra Pre-Filled Syringe Device, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 12-Oct-2022 Reporter's comment: The vaccine administration facility was the same as primary reporter. The reporter consented to follow-up. Additional supportive information: The patient received second dose of Flulaval earlier than the recommended interval, which led to shortening of vaccine schedule.
Itching that turned to a rash/ had itching; This spontaneous case was reported by a consumer and describes the occurrence of RASH PRURITIC (Itching that turned to a rash/ had itching) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included NEBIVOLOL HYDROCHLORIDE (BYSTOLIC) for AFib, APIXABAN (ELIQUIS) for Anticoagulant therapy.    On 18-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Apr-2021, the patient experienced RASH PRURITIC (Itching that turned to a rash/ had itching). At the time of the report, RASH PRURITIC (Itching that turned to a rash/ had itching) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Patient has used steroid cream as treatment.
Administrative Error.  Vaccine ordered from  local Health Department and arrived on 10/19/21 in a frozen state.  Vaccine moved to vaccine refrigerator immediately upon receipt.  Box marked with received date. Also marked expiration date to be 30 days after transfer from frozen state to refrigerated state of 2 degree to 8 degrees C. When we double checked today on 11/4/21 around 12pm we discovered that the Vaccine expired on 10/27/21 or 8 days after we received it.  We had administered the dose before we discovered this.  The patient did not have any adverse reactions.  We reported this to the manufacturer Moderna  approximately 12:30pm and was assigned a case number of MOD21-161254.
This spontaneous report as received from a male consumer reporting on himself, who on an unknown date, was vaccinated with a dose of ZOSTAVAX (dose, route and lot number not reported). The consumer reported that on an unknown date, he developed shingles after receiving ZOSTAVAX. At the time of the report, the patient's outcome was unknown. The relatedness for shingles and ZOSTAVAX was unknown. Additional information is not expected.
Miscarriage at 13-14 weeks gestation.    Estimated due date: 4/12/22.   Previous ultrasounds showed baby in good health prior to vaccine.   NIPT and nuchal translucenscy tests were negative for chromosomal abnormalities.   A post-mortem amniocentesis and pathology analysis showed no chromosomal or pathological defects.     1 previous pregnancy: vaginal delivery of healthy baby on 2/6/2018 by same provider.  Baby weighed 7 lbs, 9oz
Pt. inadvertently administered Pfizer monovalent vaccine instead of bivalent at a community event.  Pt. informed.
sick; did not received the correct amount of vaccine; This is a spontaneous report received from a contactable reporter(s) (Pharmacist) from medical information team.  A child patient received bnt162b2 (BNT162B2), intramuscular, administered in arm, administration date 10Dec2021 (Lot number: FL0007) as dose 2, 0.2 ml single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 01, LOT: FK5127, EXP: documented as 31Jan2022; but caller is not sure if that's correct), administration date: 19Nov2021, for COVID-19 immunization. The following information was reported: ILLNESS (non-serious), outcome "unknown", described as "sick"; INCORRECT DOSE ADMINISTERED (non-serious) with onset 10Dec2021, outcome "unknown", described as "did not received the correct amount of vaccine".  Additional information: Further stated that she had a patient who received their 2nd dose of the vaccine but the mother of the child said that the child moved away during the administration so she believed the child did not received the correct amount of vaccine. She stated that the mother contacted the CDC for recommendations and she was told that the child needed another injection immediately. Caller wanted to know what does "immediately" mean as the child is currently sick and cannot receive the additional dose of the vaccine as CDC recommended. Mother thinks the patient was sick and would not be able to get another dose of the vaccine for 1.5 weeks.  No follow-up attempts are possible. No further information is expected.
Bilateral eyes swelling, t-97.5, P-98, R-18, Lungs CTA, B/P 121/101, Tx-Benadryl 50mg po, Benadryl 50mg IM at 8:20 AM, 9:25 am- Prednisone 20 mg po Stat., Prednisone 20 one PO 10/07/06, Prednisone 10mg one po 10/08/06, Prednisone 10ml one po on 10/09/06, released from  at 4:30 pm on 10/06/06 12/27/06-records received and reviewed from PCP. Seen and treated in student health observation room for bilateral eye swelling. Treated with IM Benadryl, Allergy to PCN. DC to dorm after contacting parents
Swollen lymph nodes arm pit, clavicle and neck.  Have been icing/heat and alternating with acetaminophen and ibuprofen.
Whole face pain within 12 hours after vaccine. Hurt to even make any facial expressions for 4 days without relief.; This is a spontaneous report from a contactable consumer, the patient. A 14-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2588) via an unspecified route of administration in the left arm on 03Sep2021 at 19:00 (at the age of 14-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0198) via an unspecified route of administration in the right arm on 11Aug2021 at 14:00 (at the age of 14-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Sep2021 at 07:00, within 12 hours after vaccination, the patient experienced whole face pain and hurt to even make any facial expressions for 4 days without relief. The present day was day 5 and slowly dissipating. The whole face pain did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the whole face pain. On 27Aug2021, the patient underwent lab tests and procedures, which included Nasal Swab SARS CoV-2 test and the result was negative. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the event whole face pain within 12 hours after vaccine, hurt to even make any facial expressions for 4 days without relief was recovering at the time of this report.
Nasal congestion; common cold like symptoms; Headache; Chills; This spontaneous case was reported by a consumer and describes the occurrence of NASAL CONGESTION (Nasal congestion), NASOPHARYNGITIS (common cold like symptoms), HEADACHE (Headache) and CHILLS (Chills) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination.     Concurrent medical conditions included Gastritis, Allergy, Immunocompromised and HIV infection. Concomitant products included LORATADINE for Allergy NOS, OMEPRAZOLE for Gastritis, ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE (TRIUMEQ) for HIV disease, CETIRIZINE for Itching, CENTRUM VITAMINTS and FISH OIL for an unknown indication.    On 08-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Feb-2021, the patient experienced NASAL CONGESTION (Nasal congestion), NASOPHARYNGITIS (common cold like symptoms), HEADACHE (Headache) and CHILLS (Chills). On 10-Feb-2021, NASAL CONGESTION (Nasal congestion), NASOPHARYNGITIS (common cold like symptoms), HEADACHE (Headache) and CHILLS (Chills) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       No treatment medications were provided.  Patient stated that since her symptoms she had stopped taking conmed   This case was linked to MOD-2022-438834, MOD-2022-438940 (Patient Link).
3 hours after receiving vaccine, hands got hot and red, then redness crept up arms, then broke out in hives up arms, down trunk.  All of skin turned beet red and was on fire, started coughing .  Went to ER where received epi, IV steroids,  IV benadryl.
tirednss, queezy, headache, body aches, finger hrt, lymphnodes tender
Patient has a bruise and swelling at the injection site. Patient is unable to move arm easily. The reaction occurred the same day as administration.